1. ¿Qué ver en ASCO 2017?

2. Cáncer de pulmón ¿Qué ver en ASCO 2017?
Alectinib Vs. crizotinib in treatment-naive advanced ALK-positive non–small cell lung cancer (NSCLC): primary results of the global phase III ALEX study (LBA9008)
Gefitinib vs. vinorelbine+cisplatin as adjuvant treatment in stage II-IIIA (N1-N2) NSCLC with EGFR-activating mutation (ADJUVANT): a randomized, phase III trial (CTONG 1104; Abstract 8500)
Nivolumab with or without ipilimumab (Yervoy) in advanced small cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate-032 (Abstract 8503)
Impact of atezolizumab treatment beyond disease progression in advanced NSCLC: results from the randomized phase III OAK study (Abstract 9001)

3. Gastrointestinal ¿Qué ver en ASCO 2017?
OS analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer (Abstract 3507)
Nivolumab with or without ipilimumab in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer: CheckMate-032 study (Abstract 4014)
Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study (Abstract 4006)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406; Abstract 3505)
SUNSHINE: Randomized double-blind phase II trial of vitamin D supplementation in patients with previously untreated metastatic colorectal cancer (Abstract 3506)

4. Genitourinarios ¿Qué ver en ASCO 2017?
First-line avelumab (Bavencio) plus axitinib (Inlyta) therapy in patients with advanced renal cell carcinoma (RCC): results from a phase Ib trial (Abstract 4504)
IMmotion150: a phase II trial in untreated mRCC patients of atezolizumab and bevacizumab versus and following atezolizumab or sunitinib (Sutent; Abstract 4505)
A phase I/II study to assess the safety and efficacy of pazopanib (Votrient) and pembrolizumab (Keytruda) in patients with advanced RCC (Abstract 4506)
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced RCC (PROTECT; Abstract 4507)
Phase III trial of adjuvant sunitinib in patients with high-risk RCC: validation of the 16-gene Recurrence Score in stage III patients (Abstract 4508)

5. Cáncer de mama ¿Qué ver en ASCO 2017?
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy plus trastuzumab (Herceptin) plus placebo versus chemotherapy plus trastuzumab plus pertuzumab (Perjeta) as adjuvant therapy in patients with HER2-positive early breast cancer (Abstract LBA500)
OlympiAD: Phase III trial of olaparib (Lynparza) monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation (Abstract LBA4)
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy (Abstract 1000)
Overall survival results from the randomized phase II study of palbociclib (Ibrance) in combination with letrozole versus letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18; Abstract 1001)

6. Cáncer de mama ¿Qué ver en ASCO 2017?
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer; Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate, versus trastuzumab as neoadjuvant treatment in HER2-positive early breast cancer (Abstracts 509, 510)

7. Hematología ¿Qué ver en ASCO 2017?
Daratumumab in combination with carfilzomib, lenalidomide , and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): an open-label, phase Ib study (Abstract 8000)
An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma (Abstract 8002)